Tandem Diabetes Care CEO John Sheridan's 2021 pay jumps 51% to $5.7M
Tandem Diabetes Care reports 2021 executive compensation
By ExecPay News
Published: April 13, 2022
Tandem Diabetes Care reported fiscal year 2021 executive compensation information on April 13, 2022.
In 2021, six executives at Tandem Diabetes Care received on average a compensation package of $2.3M, a 1% decrease compared to previous year.
Average pay of disclosed executives at Tandem Diabetes Care
John F. Sheridan, Chief Executive Officer, received $5.7M in total, which increased by 51% compared to 2020. 36% of Sheridan's compensation, or $2.1M, was in option awards. Sheridan also received $905K in non-equity incentive plan, $690K in salary, $2.1M in stock awards, as well as $4.5K in other compensation.
For fiscal year 2021, the median employee pay was $75,196 at Tandem Diabetes Care. Therefore, the ratio of John F. Sheridan's pay to the median employee pay was 76 to one.
Brian B. Hansen, Executive Vice President, Chief Commercial Officer, received a compensation package of $1.6M, which decreased by 17% compared to previous year. 26% of the compensation package, or $424K, was in salary.
David B. Berger, Chief Operating Officer, earned $1.6M in 2021, a 18% decrease compared to previous year.
Leigh A. Vosseller, Chief Financial Officer, received $1.6M in 2021, which decreases by 18% compared to 2020.
Elizabeth A. Gasser, Executive Vice President, Chief Strategy Officer, earned $1.6M in 2021.
Susan Morrison, Chief Administrative Officer, received $1.6M in 2021, which decreases by 18% compared to 2020.
Related executives
John Sheridan
Tandem Diabetes Care
Chief Executive Officer
Leigh Vosseller
Tandem Diabetes Care
Chief Financial Officer
David Berger
Tandem Diabetes Care
Chief Operating Officer
Elizabeth Gasser
Tandem Diabetes Care
Executive Vice President, Chief Strategy Officer
Brian Hansen
Tandem Diabetes Care
Executive Vice President, Chief Commercial Officer
Susan Morrison
Tandem Diabetes Care
Chief Administrative Officer
You may also like
Source: SEC filing on April 13, 2022.